Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
Kyverna Therapeutics
KYTX
NASDAQ
Cell therapy company focused on autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- CAR t therapy takes on myasthenia gravis in major new trial Results expected Sep 2027 (estimated) May already have reported ↗ 🚀 Make-or-break